Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 15

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 15
---
 pursuant to a zero exercise price option, which is referred to in the Series B Warrant as an “alternative cashless exercise.”

Reset Provision.The exercise price of the Common Warrants will reset to a price equal to the greater of (i) the Floor Price, and (ii) the lowest
volume weighted average price during the period commencing on the first trading day immediately following the later of (x) the earlier of (A) the first (1) trading day after the
registration statement of which this prospectus forms a part is declared effective, or (B) the first (1) trading day after the date on which the holder of those securities can sell them
pursuant to Rule 144 without restriction or limitation, or (y) the first (1) trading day after the Warrant Stockholder Approval is obtained, and the number of shares issuable upon
exercise will be proportionately adjusted such that the aggregate exercise price will remain unchanged. The Floor Price is subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar
transaction.

The number of shares issuable upon exercise of the Common Warrants will increase in proportion to the amount by which the exercise price is
reduced below the initial exercise price of the applicable Common Warrant. In the event that the exercise price of the Series A Common Stock Warrants is reduced to the Floor Price pursuant to the reset provision, the 28,042,138 outstanding Series A
Common Stock Warrants would become exercisable for an aggregate of up to 280,421,380 shares of common stock at the Floor Price. The 28,042,138 outstanding Series B Common Stock Warrants would be exercisable for an aggregate of up to 84,126,414
shares of common stock assuming the Series B Common Stock Warrants are exercised pursuant to the zero exercise price provision. In the event that the exercise price of the Series B Common Stock Warrants is reduced to the Floor Price pursuant to the
reset provision, the Series B Common Stock Warrants would become exercisable for an aggregate of up to 420,632,070 shares of common stock, or an aggregate of up to 1,261,896,210 shares of common stock assuming the Series B Common Stock Warrants are
exercised pursuant to the zero exercise price provision.

Adjustment for Subsequent Issuances. Subject to certain exceptions, if the Company sells
any common stock (or securities convertible into or exercisable into common stock) at